| Added by | mollevi |
|---|---|
| Group name | EquipeAM |
| Item Type | Note |
| Note | The following values have no corresponding Zotero field: auth-address: Hopital Arnaud de Villeneuve, Maladies Respiratoires-Unite Oncologie Thoracique, Avenue du Doyen Giraud, 34295 Montpellier. Electronic address: jl-pujol@chu-montpellier.fr. Medical Oncology Unit of Respiratory Tract and Sarcomas, Thoracic Oncology Division, European Institute of Oncology, Via Ripamonti 435, 20146 Milano, Italy. Lungenfachklinik Immenhausen, Department of Thoracic OncologyRobert-Koch-Strasse 3, 34376 Immenhausen, Germany. Swedish Cancer Institute, Division of Thoracic Surgery, 1101 Madison St #900 Seattle, WA 98104, United States. Pomeranian Medical University of Szczecin, Thoracic Surgery and Transplantation Department, Alfreda Sokolowskiego Street 11, 70-891 Szczecin-Zdunowo, Poland. N.N. Petrov Institute of Oncology, Department of Tumor Biology, Pesochny-2 197758 St.-Petersburg, Russia. Universitaetsklinikum Freiburg, Department of Thoracic Surgery, Hugstetterstr. 5, 79106 Freiburg, Germany. Christiana Care Health Services, Helen F Graham Cancer Center, 4701 Ogletown Stanton Rd, Newark, 19713 DE, USA. Mayo Clinic College of Medicine, Department of Surgery, Division of General Thoracic Surgery, 200 1st St SW, Rochester, MN 55905, USA. Russian Cancer Research Center, Department of Clinical Pharmacology and Chemotherapy, 23 Kashirskoye Shosse, 115487 Moscow, Russian Federation. Krankenhaus Barmherzige Brueder, Department of Thoracic Surgery, Prufeninger Str. 86, 93049 Regensburg, Germany. GSK Vaccines, Rue de l'Institut, 89, 1330 Rixensart, Belgium. alt-title: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer accession-num: 27544054 |
| Tags | _EndnoteXML import |
| Date Added | 2018/11/14 - 12:43:03 |
| Date Modified | 2018/11/14 - 12:43:03 |
| Parent item | Safety and immunogenicity of the PRAME cancer immunotherapeutic in patients with resected non-small cell lung cancer: a phase I dose escalation study |
Institut de Recherche en Cancérologie de
